aTyr Pharma
ATYR
84 hedge funds and large institutions have $55.7M invested in aTyr Pharma in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 34 closing their positions.
54% more call options, than puts
Call options by funds: $770K | Put options by funds: $499K
8% more capital invested
Capital invested by funds: $51.5M → $55.7M (+$4.22M)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
7.26% less ownership
Funds ownership: 63.21% → 55.96% (-7.3%)
18% less funds holding
Funds holding: 103 → 84 (-19)
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.58M |
| 2 |
Two Sigma Advisers
New York
|
+$690K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$632K |
| 4 |
Morgan Stanley
New York
|
+$568K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$524K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.36M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.03M |
| 3 |
Millennium Management
New York
|
-$1.36M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$549K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$484K |
ATYR Hedge Fund Activity: Q4 2025 in Review
84 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2025, worth a combined $55.7M — up 8.2% from $51.5M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ATYR and 16 opened new positions — a net loss of 18 holders — while 25 trimmed existing stakes and 23 added.
The largest buyer was GSA Capital Partners, adding an estimated $1.58M. The largest seller was UBS Group, cutting an estimated $2.36M.
- 84 institutional investors held aTyr Pharma (ATYR) as of Q4 2025, down from 103 in Q3 2025.
- Funds reported $55.7M of aTyr Pharma stock for Q4 2025, up 8.2% quarter-over-quarter.
- 16 funds opened new aTyr Pharma positions in Q4 2025 and 34 closed out, a net change of -18 holders.
- The largest aTyr Pharma buyer in Q4 2025 was GSA Capital Partners, an estimated $1.58M added.
- The largest aTyr Pharma seller in Q4 2025 was UBS Group, an estimated $2.36M sold.
Based on aggregated 13F filings for Q4 2025.